Eli Lilly weight loss med Zepbound under investigation for immune disorders — report
by
Contributor since / Followers
Contributor since / Followers
1 month ago
jetcityimage/iStock Editorial via Getty Images
- Eli Lilly’s blockbuster medication, tirzepatide, marketed as Zepbound as a weight loss therapy, could eventually become a treatment for immune diseases.
- The drugmaker is planning a trial in the fall examining Zepbound in combination with Taltz (ixekizumab) to test a theory that tirzepatide could boost ixekizumab’s effectiveness, Bloomberg reported. Taltz is approved for several conditions including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
- Chief Scientific Officer Daniel Skovronsky told the news service that combination studies of Zepbound to treat inflammatory bowel disease are also being eyed.
- GLP-1 receptor agonists such as Zepbound are known to reduce inflammation in diabetic and obese patients, yet there have been no concrete studies conducted to determine if they are useful against autoimmune conditions.